Crossmark

Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa

Crossref DOI link: https://doi.org/10.1186/s12879-021-05905-2

Published Online: 2021-02-25

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Obasa, Adetayo Emmanuel http://orcid.org/0000-0003-0934-9586
Ambikan, Anoop T.

Gupta, Soham

Neogi, Ujjwal

Jacobs, Graeme Brendon
Funding

Funding for this research was provided by:

National Research Foundation South Africa

National Research Foundation ZA
License Information

Text and Data Mining valid from 2021-02-25

Version of Record valid from 2021-02-25
More Information

Article History

Received: 27 May 2020

Accepted: 16 February 2021

First Online: 25 February 2021

Ethics approval and consent to participate

: The study was approved by the Health Research Ethics Committee of Stellenbosch University, South Africa (N15/08/071). The study was conducted according to the ethical guidelines and principles of the Declaration of Helsinki 2013, the South African Guidelines for Good Clinical Practice and the Medical Research Council Ethical Guidelines for Research. A waiver of written informed consent was awarded to conduct sequence analyses on these samples by the Health Research Ethics Committee of Stellenbosch University, South Africa.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below